comparemela.com

Latest Breaking News On - Bharat biotechs covaxin - Page 1 : comparemela.com

Expert body recommends Bharat Biotech Covaxin for emergency use in children aged 6-12

Covaxin, bharat biotech, sec, covid 19, bharat biotech s covaxin, india, DCGI, Covaxin for emergency use in age group between 6-12 years, CDSCO, Hyderabad, Zydus Healthcare, Bharat Biotech, National Technical Advisory Group on Immunisation, Astra Zeneca vaccine, Covishield, Bharat Biotech, india

India
Bharatbiotech-covaxin
Google-news
Image-source
Drugs-controller-general
Covaxin
Bharat-biotech
Ec
Covid-19
Bharat-biotechs-covaxin
India

Biological E COVID shot gets India emergency approval for 12-18 age group

Govt points out 68% dip in daily cases, says India has to buy time to ensure high vaccination coverage | India News

India News: Lav Agrawal, Union health ministry joint secretary, on Friday, said India has to buy time to ensure high coverage of vaccination against Covid-19. He

United-states
India
Union-territories
World-health-organization
Lav-agrawal
Bharat-biotech
Ndia-news
Ndia-news-today
Oday-news
Google-news
Reaking-news

Data sharing going on with WHO to give recognition to Covaxin: Govt | India News

India News: NEW DELHI: Data sharing is going on with WHO to give recognition to Bharat Biotech's Covaxin, the government said, noting that it wants to achieve thi.

India
Bharat
Aayog-member-health-vk-paul
Bharat-biotech-international-limited
Bharat-biotech
Ndia-news
Ndia-news-today
Oday-news
Google-news
Reaking-news
Niti-aayog

IIL to produce drug substance for Covaxin - The Hindu BusinessLine

IIL to produce drug substance for Covaxin May 28, 2021 IIL is expected to produce the drug for about 10-15 million doses per month Indian Immunologicals Ltd (IIL) is planning to start the production of drug substance for Bharat Biotech’s Covaxin, from June 15. The first batch of the drug will be sent to Bharat Biotech by July, K Anand Kumar, Managing Director, IIL, said in a release issued here on Friday. IIL is expected to produce the drug for about 10-15 million doses per month. Initially, it will produce for 2-3 million doses and it will be scaled up to 6-7 million per month later in the year, Kumar said.

India
Hyderabad
Andhra-pradesh
Atmanirbhar-bharat
Rk-anand-kumar
Indian-immunologicals-ltd
Mission-covid-suraksha
Department-of-biotechnology
Bharat-biotech
Managing-director
Covid-suraksha
Indigenous-covid

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.